logo
Plus   Neg
Share
Email

Bayer Agrees To Voluntary Special Audit Of Due Diligence On Major M&A Deals

Bayer said Thursday that it agreed to allow an independent expert to review its existing specifications and requirements for conducting due diligence on major deal in the future. The company would publish reports of the expert on its website by the end of March.

Bayer reached a agreement with Christian Strenger, a stockholder of the company, on a voluntary special audit of due diligence procedures. The agreement allows Hans-Joachim Böcking of the University of Frankfurt to review the company's existing rules for conducting due diligence for major deal.

Bayer said lawyer Ralph Wollburg of Linklaters and Prof. Dr. Mathias Habersack of the University of Munich would issue more detailed statements about the legal opinions they prepared at the end of 2018 and in early 2019 concerning the duties of the Board of Management in relation to the Monsanto acquisition.

On Wednesday, Bayer said its Chairman Werner Wenning would leave the German drugs and chemicals company before his term expires, amid legal issues surrounding its weedkiller Roundup.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
Follow RTT
>